1. Academic Validation
  2. Characterization of the signaling capacities of the novel gp130-like cytokine receptor

Characterization of the signaling capacities of the novel gp130-like cytokine receptor

  • J Biol Chem. 2004 Aug 20;279(34):36112-20. doi: 10.1074/jbc.M401122200.
Alexandra Dreuw 1 Simone Radtke Stefan Pflanz Barbara E Lippok Peter C Heinrich Heike M Hermanns
Affiliations

Affiliation

  • 1 Institut für Biochemie, Universitätsklinikum der Rheinisch-Westfälischen Technischen Hochschule Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany.
Abstract

The gp130-like receptor (GPL) is a recently cloned member of the family of type I cytokine receptors. The name reflects its close relationship to gp130, the common receptor subunit of the interleukin (IL)-6-type cytokines. Indeed, the recently proposed ligand for GPL, IL-31, is closely related to the IL-6-type cytokines oncostatin M, Leukemia Inhibitory Factor, and Cardiotrophin-1. The second signal transducing receptor for IL-31 seems to be the oncostatin M receptor beta (OSMRbeta). The present study characterizes in depth the molecular mechanisms underlying GPL-mediated signal transduction. GPL is a strong activator of STAT3 and STAT5, whereas STAT1 is only marginally tyrosine-phosphorylated. We identify tyrosine residues 652 and 721 in the cytoplasmic region of the longest isoform of GPL (GPL(745)) as the major STAT5- and STAT3-activating sites, respectively. Additionally, we demonstrate JAK1 binding to GPL and its activation in heteromeric complexes with the OSMRbeta but also in a homomeric receptor complex. Most interesting, unlike OSMRbeta and gp130, GPL is insufficient to mediate ERK1/2 phosphorylation. We propose that this is due to a lack of recruitment of the tyrosine Phosphatase SHP-2 or the adaptor protein Shc to the cytoplasmic domain of GPL.

Figures